The adjuvant drugs employed for treatment of early HCC are interferons (e.g., gamma-interferon), interleukin-2, and immunomodulators such as albumin or thymosin (Ding et al., 2018; Yan et al., 2021). This evidence concerns the gene IFNG and hepatocellular carcinoma.